Catamaran Bio

We have made the difficult decision to suspend day-to-day operations at Catamaran Bio, while we pursue strategic options that will allow our programs and platform to advance. We still believe strongly in the potential of allogeneic therapies to address unmet needs in solid tumor indications, and our work to develop the TAILWIND platform has been highly productive. However, the financing environment for early stage companies like ours in the cell therapy space continues to be challenging, and the time and resources required to achieve a meaningful clinical readout made it impossible for us to proceed on our intended path. Catamaran was purpose-built to harness the potential of allogeneic (off-the-shelf) cell therapy for the treatment of solid tumors. Our lead CAR-NK programs (CAT-248 which targets CD70 expressing tumors, and CAT-179 targeting HER2 expressing tumors) are poised to enter IND-enabling studies, and we believe these programs will be meaningfully differentiated from other approaches. We are seeking strategic partners for these programs as well as the underlying technology platform which enables the engineering of cell therapies to overcome the tumor microenvironment. Please reach out to me directly at ashih@catamaranbio.com if you’d like to learn more about our programs and platform. To all the exceptional employees, investors, and partners who have joined the Catamaran journey: thank you for the tremendous privilege of co-laboring with such a talented, motivated, and authentic group of individuals. We look back on what we have accomplished together with much pride and gratitude, and we look forward to finding ways to continue working together. I’m excited and optimistic about what the future holds for all of us. Thank you again.